IL286678B2 - Compositions and methods for altering macrophage phenotype - Google Patents

Compositions and methods for altering macrophage phenotype

Info

Publication number
IL286678B2
IL286678B2 IL286678A IL28667821A IL286678B2 IL 286678 B2 IL286678 B2 IL 286678B2 IL 286678 A IL286678 A IL 286678A IL 28667821 A IL28667821 A IL 28667821A IL 286678 B2 IL286678 B2 IL 286678B2
Authority
IL
Israel
Prior art keywords
macrophages
cancer
expression
disease
disclosed
Prior art date
Application number
IL286678A
Other languages
English (en)
Hebrew (he)
Other versions
IL286678B1 (en
IL286678A (en
Original Assignee
Navidea Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navidea Biopharmaceuticals Inc filed Critical Navidea Biopharmaceuticals Inc
Publication of IL286678A publication Critical patent/IL286678A/en
Publication of IL286678B1 publication Critical patent/IL286678B1/en
Publication of IL286678B2 publication Critical patent/IL286678B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL286678A 2019-03-27 2020-03-27 Compositions and methods for altering macrophage phenotype IL286678B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962824853P 2019-03-27 2019-03-27
PCT/US2020/025326 WO2020198622A1 (en) 2019-03-27 2020-03-27 Compositions and methods for altering macrophage phenotype

Publications (3)

Publication Number Publication Date
IL286678A IL286678A (en) 2021-10-31
IL286678B1 IL286678B1 (en) 2025-03-01
IL286678B2 true IL286678B2 (en) 2025-07-01

Family

ID=72606452

Family Applications (1)

Application Number Title Priority Date Filing Date
IL286678A IL286678B2 (en) 2019-03-27 2020-03-27 Compositions and methods for altering macrophage phenotype

Country Status (8)

Country Link
US (3) US11590236B2 (https=)
EP (1) EP3946473A4 (https=)
JP (1) JP7665206B2 (https=)
BR (1) BR112021019187A2 (https=)
CA (1) CA3134974A1 (https=)
IL (1) IL286678B2 (https=)
MX (1) MX2021011703A (https=)
WO (1) WO2020198622A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
JP2025517414A (ja) * 2022-05-20 2025-06-05 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 分解性リンカーを介して新規ビスホスホネート薬物ペイロードを担持するｃｄ２０６標的化薬物送達ビヒクル
WO2024076988A2 (en) * 2022-10-03 2024-04-11 Navidea Biopharmaceuticals, Inc. Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
CN116259757B (zh) * 2023-02-06 2026-01-30 西北大学 MXene改性的金属离子预嵌入V5O12·6H2O复合材料及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells
US20170209584A1 (en) * 2014-07-17 2017-07-27 Larry Schlesinger Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218367B1 (en) * 1998-09-15 2001-04-17 Organomed Corporation Paclitaxel-carbohydrate conjugates: design, synthesis and biological evaluations
CN101801462A (zh) 2007-07-13 2010-08-11 健泰科生物技术公司 用于癌症、炎性病症和自身免疫性病症的治疗和诊断
WO2013057281A2 (en) 2011-10-21 2013-04-25 Transgene Sa Modulation of macrophage activation
CN114377143A (zh) * 2013-07-22 2022-04-22 康德乐健康414有限责任公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
MX2019004029A (es) * 2016-10-07 2019-09-27 Navidea Biopharmaceuticals Inc Compuestos y metodos para diagnosis y tratamiento de infecciones virales.
EP3522899A4 (en) * 2016-10-07 2020-05-06 Navidea Biopharmaceuticals, Inc. Compounds and compositions for treating leishmaniasis and methods of diagnosis and treating using same
CA3064277A1 (en) 2017-05-19 2018-11-22 Navidea Biopharmaceuticals, Inc. Cd206+ macrophage-specific molecular imaging probe compositions and methods and the noninvasive quantification of arterial wall macrophage infiltration in humans
US20210000920A1 (en) * 2017-12-22 2021-01-07 Atossa Therapeutics, Inc. Intraductal methods of treatment of breast disorders
BR112021019187A2 (pt) * 2019-03-27 2021-12-21 Navidea Biopharmaceuticals Inc Método para repolarização de um macrófago associado a tumor de m2 a m1, e, composto para repolarização de um macrófago associado a tumor de m2 a m1
US20210052639A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
US20170209584A1 (en) * 2014-07-17 2017-07-27 Larry Schlesinger Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
WO2016118188A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells

Also Published As

Publication number Publication date
US11590236B2 (en) 2023-02-28
US20250325681A1 (en) 2025-10-23
MX2021011703A (es) 2022-01-06
US20230218770A1 (en) 2023-07-13
EP3946473A1 (en) 2022-02-09
IL286678B1 (en) 2025-03-01
US20200306381A1 (en) 2020-10-01
IL286678A (en) 2021-10-31
CA3134974A1 (en) 2020-10-01
JP2022527176A (ja) 2022-05-31
WO2020198622A1 (en) 2020-10-01
JP7665206B2 (ja) 2025-04-21
EP3946473A4 (en) 2023-07-05
BR112021019187A2 (pt) 2021-12-21

Similar Documents

Publication Publication Date Title
US20250325681A1 (en) Compositions and methods for altering macrophage phenotype
ES2368741T3 (es) Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
CA2994165A1 (en) Methods for cancer and immunotherapy using glutamine analogues, including don
US20210145989A1 (en) Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
US20210052639A1 (en) Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
JP2022513227A (ja) 炎症性疾患のナノ粒子ベース療法
US20240024491A1 (en) Mannosylated amine dextran drug delivery vehicles with degradable disulfide/carbonate linkers targeting payloads to cd206 expressing cells
AU2020381240B2 (en) Therapeutic combinations of acalabrutinib and capivasertib to treat B-cell malignancies
CN111132672A (zh) 抗药性胶质瘤的治疗
US12006339B2 (en) CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
US12404349B2 (en) Amide linkages of sugar moieties to amine terminated leashes attached to carbohydrate polymers
US10383943B2 (en) Compositions and related methods for the treatment of cancer
US20210145965A1 (en) Method of using checkpoint kinase inhibitor therapy to modulate anti-tumoral response against cancer and sensitize gliomas to immunotherapy
HK40021256A (en) Treatment of drug resistant gliomas